Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Osteoclasts are large multinucleated cells from hematopoietic origin and are responsible for
bone resorption. A balance between osteoclastic bone resorption and osteoblastic bone …

Abstract The bisphosphonates ((HO) 2 P (O) CR 1 R 2 P (O)(OH) 2, BPs) were first shown to
inhibit bone resorption in the 1960s, but it was not until 30 years later that a detailed …

Medication-related osteonecrosis of the jaw (MRONJ), although initially believed to be
exclusively associated with bisphosphonates, has been implicated in recent reports with …

Objective This manuscript aims to provide a comprehensive review of the current knowledge
in the pathophysiology, diagnosis, prevention, and other relevant forensic and clinical …

Bisphosphonates (BPs) are the most utilized drugs for the treatment of osteoporosis, and are
usefully employed also for other pathologies characterized by abnormally high bone …

Abstract The ability of (4, 4)-armchair CNT and its three phosphate functionalized forms
(CNT-nH 2 PO 4, n= 1–3) were evaluated as novel drug delivery systems (DDSs) for the two …

Background: Invasive dental treatment in patients exposed to antiresorptive and
antiangiogenic drugs can cause medication-related osteonecrosis of the jaw (MRONJ) …

Bone undergoes constant remodeling throughout life. The cellular and biochemical
mechanisms of bone remodeling vary in a region‐specific manner. There are a number of …

The influence of the simultaneous presence of the two inhibitors of bone degradation,
strontium and zoledronate, on the direct synthesis of hydroxyapatite was explored in the …